At a Glance
- Elecoglipron is AstraZeneca’s oral GLP‑1 candidate for type 2 diabetes and weight management.
- SOLSTICE Phase IIb: primary HbA1c endpoint met at 26 weeks.
- VISTA Phase IIb: both weight‑loss co‑primary endpoints met at 26 weeks.
- Data support advancement toward Phase III as an oral alternative to injectable GLP‑1 therapies.
Written By: Pharmacally Medical News Desk
AstraZeneca’s investigational oral GLP‑1 receptor agonist elecoglipron (AZD5004) is advancing toward Phase III development, supported by positive Phase IIb data in both type 2 diabetes and chronic weight management as outlined in the company’s FY 2025 Clinical Trials Appendix. Elecoglipron is being developed as a tablet‑based GLP‑1 therapy for adults with type 2 diabetes and for people living with obesity or overweight with weight‑related comorbidities.
In type 2 diabetes, the Phase IIb SOLSTICE trial (NCT06579105) evaluated several oral doses of elecoglipron versus placebo and an active oral GLP‑1 comparator, with change in HbA1c at 26 weeks as the primary endpoint. According to the Appendix, SOLSTICE met its primary endpoint, demonstrating clinically meaningful HbA1c reductions over 26 weeks in adults with type 2 diabetes.
In obesity and overweight, the Phase IIb VISTA trial (NCT06579092) assessed multiple oral doses of elecoglipron versus placebo, using co‑primary endpoints of percentage change in body weight and the proportion of participants achieving at least 5% weight loss at 26 weeks. The Appendix reports that both primary endpoints were met, supporting elecoglipron’s potential as an oral option for medically supervised weight management.
The emerging profile of elecoglipron is notable in the context of a GLP‑1 class dominated by injectable therapies, where Novo Nordisk currently provides the main precedents for non‑injectable or oral GLP‑1‑based treatment with products such as Rybelsus (oral semaglutide) and Wegovy (semaglutide for obesity). If confirmed in Phase III, elecoglipron could offer an additional oral GLP‑1 option for patients and clinicians seeking alternatives to injectable regimens.
Beyond efficacy trials, AstraZeneca’s Appendix highlights an extensive supporting programme for elecoglipron, including Phase I studies in healthy volunteers, renal and hepatic impairment, bioavailability, and key drug–drug interaction assessments. Within the company’s broader cardiometabolic pipeline, this package underscores AstraZeneca’s intent to develop elecoglipron as a comprehensive oral GLP‑1 therapy for type 2 diabetes and chronic weight management, with Phase IIb success now providing the basis for planned Phase III evaluation.
Reference
Clinical Trials Appendix FY 2025 Results Update, 10 February 2026, Elecoglipron, Page No.106, AZN IR: CTA
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults with Type 2 Diabetes Mellitus. (SOLSTICE), ClinicalTrials.gov ID NCT06579105, https://clinicaltrials.gov/study/NCT06579105
Effects of AZD5004 in Adults Who Are Living with Obesity or Overweight With at Least 1 Weight-related Comorbidity (VISTA), ClinicalTrials.gov ID NCT06579092, https://clinicaltrials.gov/study/NCT06579092